SEC form
4
Accepted by SEC
21 Feb 2024, 16:20:10 UTC
Prior SEC filing
07 Nov 2023
Source filing
View source filing
Filing notes and source

Key filing fact

Lumira Capital Investment Management Inc. filed Form 4 for enGene Holdings Inc. (ENGN) on 21 Feb 2024.

Key facts

  • This page summarizes Lumira Capital Investment Management Inc.'s Form 4 filing for enGene Holdings Inc. (ENGN).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 21 Feb 2024, 16:20.

Change

  • Previous filing in this sequence was filed on 07 Nov 2023.
  • Current net transaction value: +$8,000,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENGN transaction

Common Shares

Award

Transaction value
$6,449,650
Shares
+644,965
Change %
+185%
Price
$10.00
Shares after
993,651
Date
20 Feb 2024
Ownership
Held by Lumira Ventures IV, L.P.
Footnotes
F1, F2, F5
ENGN transaction

Common Shares

Award

Transaction value
$1,550,350
Shares
+155,035
Change %
+185%
Price
$10.00
Shares after
238,851
Date
20 Feb 2024
Ownership
Held by Lumira Ventures IV (International), L.P.
Footnotes
F1, F2, F5
ENGN holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,341,790
Date
20 Feb 2024
Ownership
Held by Lumira Ventures III, L.P.
Footnotes
F1, F3, F5
ENGN holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
44,647
Date
20 Feb 2024
Ownership
Held by Lumira Ventures III (International), L.P.
Footnotes
F1, F3, F5
ENGN holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,077,386
Date
20 Feb 2024
Ownership
Held by Merck Lumira Biosciences Fund, L.P.
Footnotes
F1, F4, F5
ENGN holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
152,974
Date
20 Feb 2024
Ownership
Held by Merck Lumira Biosciences Fund (Quebec), L.P.
Footnotes
F1, F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Lumira Capital Investment Management Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

This Form 4 is filed jointly by Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"), Lumira Capital Investment Management Inc. ("Lumira Mgmt"), Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc. and Lumira GP Holdings Co. (collectively, the "Reporting Person").

Footnote F2

Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt.

Footnote F3

Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Mgmt. Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co.

Footnote F4

Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co.

Footnote F5

Gerald Brunk, a director of the Issuer, is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt and reports his beneficial ownership of these securities on a separate Form 4. Each of Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any.

SEC remarks

Mr. Brunk serves on the Issuer's Board of Directors (the "Board") as a representative of the Reporting Person. By virtue of his representation on the Board, for purposes of Section 16 of the Exchange Act, the Reporting Person may be deemed to be a director of the Issuer by deputization of Mr. Brunk.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .